Men's Health News

RSS

GWAS suggests genetic variant with increased oncogene expression for cancer study

The study, published July 13th in Genome Research, showcases a new protocol for studying the activity of cancer-risk variants suggested by GWAS studies. The results also underscore the dramatic consequences of small genetic changes even in the vast stretches of DNA, known as "gene deserts," that do not code for proteins.

13 Jul 2010

Depression increases cardiovascular problems in men with erectile dysfunction

A new study in the Journal of Sexual Medicine found that the presence of depressive symptoms in men with erectile dysfunction constitutes a risk factor for a major cardiovascular event.

13 Jul 2010

Differences in response to taste of fat between obese and lean men

Research to be presented at the Annual Meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior, finds marked differences between obese and lean men in how they respond to the taste of fat. Fat also is less effective in obese men in stimulating certain gut hormones that are released into the bloodstream and normally suppress appetite.

13 Jul 2010

Theragenics signs supply agreement with Oncura for TheraSeed palladium-103 brachytherapy seeds

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has signed an agreement with Oncura, Inc. for the distribution of TheraSeed® palladium-103 brachytherapy seeds. Oncura is a unit of GE Healthcare. Under the terms of the agreement, Theragenics will be the exclusive palladium-103 seed supplier to Oncura, subject to certain pre-existing vendor agreements, for the treatment of prostate cancer in the U.S. and Canada.

12 Jul 2010

Males with faulty BRCA2 genes at risk of breast cancer

Men who carry a faulty version of the BRCA2 gene have an estimated one-in-15 chance of developing breast cancer by the time they reach 70, British scientists have found.

9 Jul 2010

MHN endorses 'The American Journal of Men's Health'

The American Journal of Men's Health (published by SAGE) is now endorsed by Men's Health Network.

9 Jul 2010

Men with higher baseline PSA value more likely to die from prostate cancer, say researchers

Men who have a baseline PSA value of 10 or higher the first time they are tested are up to 11 times more likely to die from prostate cancer than are men with lower initial values, according to Duke University Medical Center researchers.

9 Jul 2010

Experts to sound alarm on the worsening global AIDS crisis among MSM

Many of the world's leading experts on the health and human rights of men who have sex with men (MSM) will gather on Tuesday, July 20 for a press briefing to sound the alarm on the worsening global AIDS crisis among MSM -- and the role that tragic human rights violations and ignorance play in the spread of the epidemic.

8 Jul 2010

Nymox reports positive new results from pooled analysis of NX-1207 clinical trials for BPH

Nymox Pharmaceutical Corporation reported today positive new results from pooled analysis of completed clinical trials of NX-1207, the Company's investigational drug for BPH. The trial data shows that patients receiving NX-1207 recorded significant quantitative improvement in the important symptom of urgent need to urinate.

8 Jul 2010

Patients are not presented with information about prostate cancer treatment options: Urologists

At the recent meeting of the American Urological Association in San Francisco, researchers presented studies regarding the decision making process men go through when considering proposed prostate cancer treatments. Dr. Vorstman, renowned Florida urologist, believes these studies would have more meaning if patients were presented with information about prostate cancer treatment options in a different fashion.

7 Jul 2010

Study finds additional targets for new therapies to treat advanced prostate cancer patients

In its early stages, prostate cancer requires androgens (hormones that promote the development and maintenance of male sex characteristics) for growth, and current first-line therapies target the receptor for these hormones to slow cancer's development and spread.

7 Jul 2010

Erectile dysfunction drug user over 40 more likely to have sexually transmitted diseases

Physicians who prescribe erectile dysfunction drugs for their male patients should be sure to discuss the importance of safer sex practices, even with older patients: that is an important implication of a report in the July 6 issue of Annals of Internal Medicine. The analysis of insurance records of more than 1.4 million U.S. men over 40 found that those who used ED drugs were more likely to have sexually transmitted diseases than were non-users.

6 Jul 2010

ZERO demands ACS apology on effectiveness of PSA test

With a new study showing the PSA test reduces the prostate cancer death rate by 44 percent, ZERO – The Project to End Prostate Cancer demands an apology for all at risk of the disease from the American Cancer Society, which has long discounted the importance of prostate cancer testing.

3 Jul 2010

Modified Citrus Pectin holds promise against prostate cancer

Researchers at Columbia University recently analyzed the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines. The results, as reported by lead researcher Dr. Aaron Katz in the most recent publication of Integrative Cancer Therapies, show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time and dose-dependent manner.

2 Jul 2010

Researchers develop first model of hormone-induced human prostate cancer initiation and progression

Progress toward understanding the role of sex hormones in the growth of prostate cancer—the most common cancer in U.S. men—has been hindered by the lack of a suitable laboratory research model. Now researchers say they have developed the first model of hormone-induced human prostate cancer initiation and progression.

2 Jul 2010

Medicare weighs cost, benefit of covering Dendreon's Provenge for prostate cancer

The announcement that the Centers for Medicare and Medicaid Services would do this analysis "was the latest hurdle in Dendreon's push to get its Provenge treatment used. If the Centers for Medicare and Medicaid Services covers Provenge, that would increase the number of patients eligible and likely force private insurers to do the same.

2 Jul 2010

Older men with high testosterone levels more likely to have heart attacks

A large U.S. multicenter study shows that older men with higher testosterone levels are more likely to have a heart attack or other cardiovascular disease in the future. The results were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.

2 Jul 2010

USPTO awards Furiex method patent for dapoxetine in treatment of premature ejaculation

Furiex Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office issued a patent on May 18, 2010, for the method for treatment of premature ejaculation using dapoxetine. Furiex developed dapoxetine in collaboration with Alza Corporation and its affiliates. U.S. Patent No. 7,718,705 includes claims directed to dosing dapoxetine on an as-needed basis, capturing the advantage dapoxetine has over other compounds in the same class, which require a pre-loading period for efficacy.

2 Jul 2010

Highly specific assay developed to detect ERG alterations in prostate cancer

Researchers at the Uniformed Services University of the Health Sciences Center for Prostate Disease Research, in collaboration with investigators at the Armed Forces Institute of Pathology and Walter Reed Army Medical Center, have developed a highly specific assay for the detection of ERG, a protein associated with tumor formations which is present in more than half of all prostate cancers.

1 Jul 2010

Endo responds to FDA Complete Response letter for FORTESTA NDA

Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.

1 Jul 2010

Men's Health News

GWAS suggests genetic variant with increased oncogene expression for cancer study

Depression increases cardiovascular problems in men with erectile dysfunction

Differences in response to taste of fat between obese and lean men

Theragenics signs supply agreement with Oncura for TheraSeed palladium-103 brachytherapy seeds

Males with faulty BRCA2 genes at risk of breast cancer

MHN endorses 'The American Journal of Men's Health'

Men with higher baseline PSA value more likely to die from prostate cancer, say researchers

Experts to sound alarm on the worsening global AIDS crisis among MSM

Nymox reports positive new results from pooled analysis of NX-1207 clinical trials for BPH

Patients are not presented with information about prostate cancer treatment options: Urologists

Study finds additional targets for new therapies to treat advanced prostate cancer patients

Erectile dysfunction drug user over 40 more likely to have sexually transmitted diseases

ZERO demands ACS apology on effectiveness of PSA test

Modified Citrus Pectin holds promise against prostate cancer

Researchers develop first model of hormone-induced human prostate cancer initiation and progression

Medicare weighs cost, benefit of covering Dendreon's Provenge for prostate cancer

Older men with high testosterone levels more likely to have heart attacks

USPTO awards Furiex method patent for dapoxetine in treatment of premature ejaculation

Highly specific assay developed to detect ERG alterations in prostate cancer

Endo responds to FDA Complete Response letter for FORTESTA NDA

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News